Harenberg J - Search Results

1

Risk stratification and heparin prophylaxis to prevent venous thromboembolism in pregnant women.

Bauersachs RM, Dudenhausen J, Faridi A, Fischer T, Fung S, Geisen U, Harenberg J, Herchenhan E, Keller F, Kemkes-Matthes B, Schinzel H, Spannagl M, Thaler CJ; EThIG Investigators. Bauersachs RM, et al. Among authors: harenberg j. Thromb Haemost. 2007 Dec;98(6):1237-45. doi: 10.1160/th07-05-0329. Thromb Haemost. 2007. PMID: 18064320 Clinical Trial.

2

Biological activity and safety of the subcutaneous administration of high doses of low molecular weight heparin for 8 days in human volunteers.

Harenberg J, Giese C, Dempfle CE, Stehle G, Heene DL. Harenberg J, et al. Thromb Haemost. 1989 Jun 30;61(3):357-62. Thromb Haemost. 1989. PMID: 2552604

3

Primary and secondary long-term prophylaxis of thromboembolism in outpatients with the low-molecular-weight heparin Kabi 2165.

Harenberg J, Leber G, Raedsch R, Zimmermann R, Schwarz F, Kübler W. Harenberg J, et al. Haemostasis. 1988;18 Suppl 3:78-81. doi: 10.1159/000215872. Haemostasis. 1988. PMID: 2840378 Clinical Trial.

4

Monitoring of heparin and low molecular weight heparin with capillary and venous whole blood.

Harenberg J, Giese C, Dempfle CE, Stehle G, Heene DL. Harenberg J, et al. Thromb Haemost. 1988 Dec 22;60(3):377-81. Thromb Haemost. 1988. PMID: 2853458

5

Lack of anti-factor Xa activity in umbilical cord vein samples after subcutaneous administration of heparin or low molecular mass heparin in pregnant women.

Harenberg J, Schneider D, Heilmann L, Wolf H. Harenberg J, et al. Haemostasis. 1993 Nov-Dec;23(6):314-20. doi: 10.1159/000216894. Haemostasis. 1993. PMID: 8034237 Clinical Trial.

6

Subcutaneous low-molecular-weight heparin versus standard heparin and the prevention of thromboembolism in medical inpatients. The Heparin Study in Internal Medicine Group.

Harenberg J, Roebruck P, Heene DL. Harenberg J, et al. Haemostasis. 1996 May-Jun;26(3):127-39. doi: 10.1159/000217198. Haemostasis. 1996. PMID: 8738587 Clinical Trial.

7

Fixed-dose, body weight-independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators.

Harenberg J, Schmidt JA, Koppenhagen K, Tolle A, Huisman MV, Büller HR. Harenberg J, et al. Thromb Haemost. 2000 May;83(5):652-6. Thromb Haemost. 2000. PMID: 10823256 Clinical Trial.

8

Risk assessment of venous thromboembolism in medical patients.

Harenberg J. Harenberg J. Semin Hematol. 2000 Jul;37(3 Suppl 5):3-6. doi: 10.1016/s0037-1963(00)90092-1. Semin Hematol. 2000. PMID: 11055888 Review.

9

Fixed-dose, body weight-independent subcutaneous low molecular weight heparin Certoparin compared with adjusted-dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis.

Riess H, Koppenhagen K, Tolle A, Kemkes-Matthes B, Gräve M, Patek F, Drexler M, Siemens HJ, Harenberg J, Weidinger G, Brom J, Haas S; TH-4 Study Group. Riess H, et al. Among authors: harenberg j. Thromb Haemost. 2003 Aug;90(2):252-9. doi: 10.1160/TH02-09-0061. Thromb Haemost. 2003. PMID: 12888872 Clinical Trial.

10

Heparin-induced thrombocytopenia: pathophysiology and new treatment options.

Harenberg J, Jörg I, Fenyvesi T. Harenberg J, et al. Pathophysiol Haemost Thromb. 2002 Sep-Dec;32(5-6):289-94. doi: 10.1159/000073583. Pathophysiol Haemost Thromb. 2002. PMID: 13679659 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

329 results

Search Page

Filters